Cafotrex 5 Tablet: Methotrexate IP 5 mg - Dual-Action Specialty Therapy

Mechanism of Action: Folic Acid Antagonism and Cellular Proliferation Control

Primary Oncology Use: Maintenance Therapy for Acute Lymphoblastic Leukemia (ALL)

High-Volume Specialty Applications: Psoriasis and Rheumatoid Arthritis (RA)

Ensuring Bioavailability and Patient Safety with IP Grade Methotrexate
Secure Your Monopoly: Cafotrex 5 PCD Pharma Franchise in Chronic & Oncology Care

Home/Products /methotrexate-ip-5-mg-tablet

About the Product

Description


Cafotrex 5 Tablet (Methotrexate IP 5 mg) is a globally recognized anti-metabolite and immunosuppressant essential in both specialized oncology and chronic autoimmune care. Its versatility makes it a perpetually high-demand product in the specialty medicine market.

Mechanism and Impact:Methotrexate works as a folic acid antagonist by inhibiting the enzyme dihydrofolate reductase (DHFR). This action prevents the synthesis of DNA, RNA, and proteins, thereby slowing down the rapid proliferation of two types of cells:

  1. Cancer Cells: Essential for cancer therapy (e.g., ALL maintenance, Choriocarcinoma).

  2. Immune and Skin Cells: Controls the hyperactive cell turnover seen in severe autoimmune conditions (e.g., severe psoriasis and active rheumatoid arthritis).

Key Therapeutic Uses:

  • Oncology: Crucial for the maintenance phase of ALL and for treating certain solid tumors and lymphomas.

  • Autoimmune: The standard, low-dose regimen for managing severe, active Rheumatoid Arthritis and refractory Psoriasis.

We offer an exclusive PCD Pharma Franchise opportunity for Cafotrex 5, giving partners a profitable, dual-target entry into both the oncology and specialty autoimmune sectors.

May cause nausea, vomiting, mouth ulcers, fatigue, dizziness, and elevated liver enzymes. Long-term use may lead to bone marrow suppression, liver toxicity, and lung complications. Regular monitoring is essential.

Rheumatoid arthritis and other inflammatory joint disorders Psoriasis (severe, recalcitrant forms) Certain cancers like acute lymphoblastic leukemia (ALL) and non-Hodgkin's lymphoma As part of chemotherapy regimens or in low doses for autoimmune disease management

To be taken only under strict medical supervision. Avoid alcohol to prevent liver toxicity. Contraindicated in pregnancy – may cause birth defects. Routine blood tests required to monitor blood counts, liver, and kidney function. Folic acid supplementation may be advised to reduce side effects.

Store at room temperature (below 25°C) in a cool, dry place, away from light and moisture. Keep out of reach of children. Do not use if the tablet appears damaged or discolored.

Get in Touch

Regulatory Compliance & Professional Verification

This catalog is a digital representation of the Cafoli Lifecare portfolio and is intended for use by authorized pharmaceutical distributors and PCD franchise partners.

  • No Consumer Sale: We do not entertain retail inquiries or direct sales to patients.
  • Information Accuracy: While we strive for accuracy, product availability, packaging, and regulatory status may change based on CDSCO guidelines and state-specific drug laws.
  • Medical Advice: Patients are strictly advised not to self-medicate or use this information for treatment. Always consult a qualified medical practitioner.
  • Licensing: All business associations are subject to the submission of valid GST and Drug License (DL) documentation.

Frequently Asked Questions

What are the business opportunities for Methotrexate IP 5 mg Tablet in the PCD pharma franchise market?

Methotrexate IP 5 mg Tablet is a disease-modifying antirheumatic drug (DMARD) and antimetabolite used in the management of rheumatoid arthritis, severe psoriasis, certain autoimmune disorders, and some cancers under specialist supervision. It works by reducing abnormal immune system activity and slowing down cell proliferation. It is a strong rheumatology, dermatology, and oncology specialty segment product for medical distributors, wholesalers, and pharma franchise partners in the PCD pharma pharma franchise market.

Why should medical distributors include this tablet in their range?

Medical distributors and wholesalers can benefit from steady and long-term prescription demand from rheumatologists, dermatologists, and oncologists. Since it is used in chronic therapies, it ensures consistent repeat prescriptions and stable monthly sales.

Does Cafoli Lifecore offer PCD pharma franchise opportunities for this product?

Yes, Cafoli Lifecare offers PCD pharma pharma franchise opportunities in specialty-care formulations including rheumatology, dermatology, and oncology segments with monopoly rights, quality manufacturing standards, and reliable supply support for distributors and medical agencies.

What benefits do wholesalers get by partnering for this specialty product?

Wholesalers and medical agencies benefit from long-term chronic disease management demand, specialist prescriptions, and continuous therapy cycles, making it a stable and high-value pharmaceutical category when partnered with Cafoli Lifecare.

How can I become a distributor or franchise partner for Methotrexate IP 5 mg Tablet?

Medical distributors, stockists, and pharma professionals interested in specialty-care formulations can contact Cafoli Lifecare to discuss product availability, regulatory requirements, and PCD pharma franchise opportunities in the rheumatology, dermatology, and oncology segments.